Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29573941

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 May
First author
Dummer R

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 May;19(5):580-581. doi: 10.1016/S1470-2045(18)30161-X.
    note
    Source null
    related pmid
    29573940
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2018 Jun;15(6):344-345. doi: 10.1038/s41571-018-0019-x.
    note
    Source null
    related pmid
    29651128
    relationship
    Comment in

Authors and identifiers

  1. name
    Dummer R
    type
    Author
  2. name
    Ascierto PA
    type
    Author
  3. name
    Gogas HJ
    type
    Author
  4. name
    Arance A
    type
    Author
  5. name
    Mandala M
    type
    Author
  6. name
    Liszkay G
    type
    Author
  7. name
    Garbe C
    type
    Author
  8. name
    Schadendorf D
    type
    Author
  9. name
    Krajsova I
    type
    Author
  10. name
    Gutzmer R
    type
    Author
  11. name
    Chiarion-Sileni V
    type
    Author
  12. name
    Dutriaux C
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dummer R
    type
    Author
  2. name
    Ascierto PA
    type
    Author
  3. name
    Gogas HJ
    type
    Author
  4. name
    Arance A
    type
    Author
  5. name
    Mandala M
    type
    Author
  6. name
    Liszkay G
    type
    Author
  7. name
    Garbe C
    type
    Author
  8. name
    Schadendorf D
    type
    Author
  9. name
    Krajsova I
    type
    Author
  10. name
    Gutzmer R
    type
    Author
  11. name
    Chiarion-Sileni V
    type
    Author
  12. name
    Dutriaux C
    type
    Author
bibliography ids
  1. nci-bib-b2a7de8f5b63de843ce1bf94
book metadata
content sha256
48eb6fae31192e0a32e302beacaa5c05c949f0f347d99389229d893b37e84f77
document type
citation
dois
  1. 10.1016/S1470-2045(18)30142-6
electronic publication date
display
2018 Mar 21
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29573941
immutable id
pubmed:29573941@48eb6fae31192e0a32e302beacaa5c05c949f0f347d99389229d893b37e84f77
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
603-615
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 May;19(5):580-581. doi: 10.1016/S1470-2045(18)30161-X.
    note
    Source null
    related pmid
    29573940
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2018 Jun;15(6):344-345. doi: 10.1038/s41571-018-0019-x.
    note
    Source null
    related pmid
    29651128
    relationship
    Comment in
outcomes validated
false
pmid
29573941
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
1f94f5cb8b70e945ea7b9daf7df7fbb50a0913138bd73dbac5f7f91ea0ce50fe
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 May
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29573941/
title
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Preserved source evidence · Not medical advice